Mohammadi E, et al. - In β-thalassemia major patients, researchers gauged the impacts of curcumin, the active polyphenol in turmeric, on iron overload, hepcidin level, and liver function. In this double-blind randomized controlled clinical trial, 68 β-thalassemia major patients were randomized to either 500 mg curcumin capsules twice daily or placebo for 12 weeks. Findings demonstrated that in both groups, hepcidin and other variables did not change significantly. Iron burden and liver dysfunction were lessened with curcumin administration by reducing nontransferrin bound iron, alanine aminotransferase, and aspartate aminotransferase levels in patients with β-thalassemia major.